Etoricoxib in contemporary rheumatology and pain management: clinical efficacy and treatment accessibility illustrated by Forsanek
Summary. Pain and inflammatory processes remain among the most common clinical manifestations in rheumatology, neurology, and musculoskeletal disorders, significantly reducing patients’ quality of life and work capacity. Chronic pain is multifactorial in nature and often coexists with comorbid conditions, necessitating a comprehensive therapeutic approach. Selective cyclooxygenase-2 (COX-2) inhibitors, particularly etoricoxib, demonstrate high clinical efficacy in controlling pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other inflammatory conditions. Forsanek, a domestically available formulation of etoricoxib, provides evidence-based efficacy, a favorable safety profile, and economic accessibility, allowing therapy individualization through three dosing options (60, 90, and 120 mg). Clinical and pharmacoeconomic studies confirm that Forsanek effectively controls both acute and chronic pain, reduces the need for additional NSAIDs, and enhances treatment adherence. In the contemporary Ukrainian context, the combination of clinical efficacy, safety, and affordability makes Forsanek an optimal tool for personalized therapy in patients with chronic pain syndromes and inflammatory joint conditions.
Leave a comment